JNJ

192.92

+0.42%↑

ABT

128.49

+0.14%↑

MDT

96.22

+0.28%↑

VEEV

288.33

-0.96%↓

A

145.3

+0.09%↑

JNJ

192.92

+0.42%↑

ABT

128.49

+0.14%↑

MDT

96.22

+0.28%↑

VEEV

288.33

-0.96%↓

A

145.3

+0.09%↑

JNJ

192.92

+0.42%↑

ABT

128.49

+0.14%↑

MDT

96.22

+0.28%↑

VEEV

288.33

-0.96%↓

A

145.3

+0.09%↑

JNJ

192.92

+0.42%↑

ABT

128.49

+0.14%↑

MDT

96.22

+0.28%↑

VEEV

288.33

-0.96%↓

A

145.3

+0.09%↑

JNJ

192.92

+0.42%↑

ABT

128.49

+0.14%↑

MDT

96.22

+0.28%↑

VEEV

288.33

-0.96%↓

A

145.3

+0.09%↑

Search

Corcept Therapeutics Inc

Aperta

SettoreSettore sanitario

73.11 -4.12

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

72.78

Massimo

76.63

Metriche Chiave

By Trading Economics

Entrata

15M

35M

Vendite

37M

194M

P/E

Media del settore

63.866

36.442

Margine di Profitto

18.078

Dipendenti

500

EBITDA

23M

27M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+72.18% upside

Dividendi

By Dow Jones

Utili prossimi

29 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

460M

7.8B

Apertura precedente

77.23

Chiusura precedente

73.11

Notizie sul Sentiment di mercato

By Acuity

26%

74%

49 / 371 Classifica in Healthcare

Corcept Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ott 2025, 23:55 UTC

Azioni calde

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 ott 2025, 23:49 UTC

Utili

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 ott 2025, 21:40 UTC

Utili

Waste Connections 3Q Revenue Rises

21 ott 2025, 21:14 UTC

Utili
I principali Market Mover

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 ott 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 ott 2025, 20:57 UTC

Acquisizioni, Fusioni, Takeovers

DraftKings to Launch Prediction Markets Platform

21 ott 2025, 20:38 UTC

Utili

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 ott 2025, 20:35 UTC

Utili

Capital One 3Q Sales, Profit Jump

21 ott 2025, 20:32 UTC

Utili

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 ott 2025, 23:44 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 ott 2025, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 ott 2025, 23:39 UTC

Discorsi di Mercato

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 ott 2025, 23:36 UTC

Discorsi di Mercato

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 ott 2025, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Scentre Says This Forms Part of Capital Management Strategy

21 ott 2025, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 ott 2025, 22:54 UTC

Acquisizioni, Fusioni, Takeovers

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 ott 2025, 21:09 UTC

Discorsi di Mercato
Utili

Netflix Creators Have Started Using AI in Production -- Market Talk

21 ott 2025, 20:58 UTC

Discorsi di Mercato
Utili

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

21 ott 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

21 ott 2025, 20:43 UTC

Utili

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 ott 2025, 20:41 UTC

Utili

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 ott 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 ott 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 ott 2025, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 ott 2025, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 ott 2025, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 ott 2025, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 ott 2025, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 ott 2025, 20:29 UTC

Utili

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Corcept Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

72.18% in crescita

Previsioni per 12 mesi

Media 135.33 USD  72.18%

Alto 145 USD

Basso 121 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Corcept Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

49 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat